Belite Bio, Inc. ADR (BLTE) Price & Analysis

Compare

56 Followers

BLTE Stock Chart & Stats

$190.30

-$1.45(-2.47%)

At close: Jan 08 4:00 PM EST

$190.30

-$1.45(-2.47%)

Day’s Range― - ―

52-Week Range$49.00 - $200.00

Previous CloseN/A

Volume15.47K

Average Volume (3M)64.23K

Market Cap

$6.64B

Enterprise Value$6.48B

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.96

Next Earnings

May 19, 2026

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding37,514,630

10 Day Avg. Volume75,810

30 Day Avg. Volume64,229

Financial Highlights & Ratios

PEG Ratio63.44

Price to Book (P/B)13.21

Price to Sales (P/S)0.00

P/FCF Ratio-65.58

Enterprise Value/Market Cap0.98

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-132.21

Forecast

1Y Price Target

$196.20

Price Target Upside3.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.4

Revenue Forecast (FY)$50.00M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPhase 3 DRAGON data demonstrated meaningful slowing of retinal lesion growth with favorable tolerability, supporting expectations for strong clinical use in Stargardt disease type 1.

Financial Strength For CommercializationA significant capital raise combined with existing cash resources improves the company's ability to finance regulatory submissions and build commercial infrastructure across major markets.

First‑in‑class Commercial OpportunityPositioning as a potential first approved therapy for Stargardt disease type 1 addresses a clear unmet pediatric need and could drive rapid adoption by retina specialists.

Bears Say

Potential FDA Confirmatory Trial RequirementA possible FDA request for an additional confirmatory study could postpone U.S. market entry and push back anticipated revenue generation.

Regulatory Approval Pathway UncertaintyLack of prior approval precedent in Stargardt disease type 1 creates uncertainty around regulatory expectations and could complicate approval processes in key regions.

Reimbursement And Pricing PressuresHigh expected treatment cost may prompt payer restrictions or access hurdles that could limit early patient uptake despite clinical need.

Belite Bio, Inc. ADR News

Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran

The major averages were lower throughout the morning but have bounced back near noon as markets react to...

8h ago

Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)

“2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON...

14h ago

BLTE

Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year

06:11 EST Belite Bio (BLTE) sees FY25 adjusted EPS ($1.15) vs. ($89c) last year Published first on TheFly...

14h ago

BLTE

Belite Bio price target raised to $223 from $194 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $223 from $194 and...

12d ago

BLTE

Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win

Belite Bio, Inc. ADR ( ($BLTE) ) has provided an update. Belite Bio reported preliminary, unaudited fourth-quarter and...

14h ago

BLTE

Is BLTE a Buy, Before Earnings?

Belite Bio, Inc. ADR (BLTE) is scheduled to report 4th quarter earnings on 03/02/2026, after the market closes....

3d ago

BLTE

Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease

Belite Bio, Inc. ADR ( ($BLTE) ) has shared an announcement. On January 27, 2026, Belite Bio announced...

1M ago

BLTE

Belite Bio completes enrollment in DRAGON II trial of tinlarebant

Belite Bio (BLTE) announced the completion of enrollment of 60 subjects, including 15 Japanese subjects, in the Phase...

1M ago

BLTE

Netflix, Meta upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

AAP

AIR

Belite Bio initiated with a Buy at BofA

BofA analyst Tazeen Ahmad initiated coverage of Belite Bio (BLTE) with a Buy rating and $195 price target...

1M ago

BLTE

Belite Bio initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of Belite Bio (BLTE) with an Overweight rating and $191 price target The firm...

2M ago

BLTE

Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential

Belite Bio, Inc. ADR (BLTE) has received a new Buy rating, initiated by Morgan Stanley analyst, Judah Frommer....

2M ago

BLTE

Belite Bio participates in a conference call with H.C. Wainwright

Healthcare Analyst Yi Chen, along with Chief Medical Officer Scholl discuss the company’s reported data from the Phase...

3M ago

BLTE

Belite Bio Prices $350 Million ADS Offering to Boost Drug Development

Belite Bio, Inc. ADR ( ($BLTE) ) just unveiled an announcement. On December 1, 2025, Belite Bio announced...

3M ago

BLTE

BLTE FAQ

What was Belite Bio, Inc. ADR’s price range in the past 12 months?

Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $200.00 in the past 12 months.

What is Belite Bio, Inc. ADR’s market cap?

Belite Bio, Inc. ADR’s market cap is $6.64B.

When is Belite Bio, Inc. ADR’s upcoming earnings report date?

Belite Bio, Inc. ADR’s upcoming earnings report date is May 19, 2026 which is in 77 days.

How were Belite Bio, Inc. ADR’s earnings last quarter?

Belite Bio, Inc. ADR released its earnings results on Mar 02, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.166.

Is Belite Bio, Inc. ADR overvalued?

According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Belite Bio, Inc. ADR pay dividends?

Belite Bio, Inc. ADR does not currently pay dividends.

What is Belite Bio, Inc. ADR’s EPS estimate?

Belite Bio, Inc. ADR’s EPS estimate is -0.57.

How many shares outstanding does Belite Bio, Inc. ADR have?

Belite Bio, Inc. ADR has 37,514,630 shares outstanding.

What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?

Belite Bio, Inc. ADR reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went up 3.666%.

Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?

Currently, no hedge funds are holding shares in BLTE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Belite Bio, Inc. ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-32.30%

Trailing 12-Months

Asset Growth

32.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Belite Bio, Inc. ADR

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc. ADR (BLTE) Earnings & Revenues

Historic Earnings Reports

BLTE Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects significant regulatory progress and strong financial positioning through successful funding. However, these positives are counterbalanced by increased losses and rising expenses, primarily due to share-based compensation and trial costs.View all BLTE earnings summaries

BLTE Stock 12 Month Forecast

Average Price Target

$196.20

▲(3.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","98":"$98","140":"$140","182":"$182","224":"$224"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$223.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":196.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$196.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$185.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,98,140,182,224],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.31,177.1323076923077,180.95461538461538,184.77692307692308,188.59923076923076,192.42153846153846,196.24384615384616,200.06615384615384,203.88846153846154,207.71076923076924,211.53307692307692,215.35538461538462,219.1776923076923,{"y":223,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.31,175.07076923076923,176.83153846153846,178.59230769230768,180.3530769230769,182.11384615384614,183.87461538461537,185.63538461538462,187.39615384615385,189.15692307692308,190.9176923076923,192.67846153846153,194.43923076923076,{"y":196.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.31,174.20923076923077,175.10846153846154,176.0076923076923,176.90692307692308,177.80615384615385,178.70538461538462,179.60461538461539,180.50384615384615,181.40307692307692,182.3023076923077,183.20153846153846,184.10076923076923,{"y":185,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >